期刊
CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY
卷 15, 期 2, 页码 147-152出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MED.0b013e3282f7026f
关键词
ACE inhibitors; angiotensin receptor blocker; glycemic control; insulin sensitivity; renin-angiotensin-aldosterone system
资金
- King
- Bayer
- Eli-Lilly
- Sanofi-Aventis
- Medtronic
Purpose of review Diabetes mellitus is an exploding epidemic costing billions of dollars yearly. Type 2 diabetes mellitus is characterized by insulin resistance and is closely associated with arterial hypertension. Emerging literature has demonstrated that modulation of the renin-angiotensin-aldosterone system by use of angiotensin-converting enzyme inhibitors or angiotensn II receptor blockers leads to improved insulin sensitivity, glycemic control and possibly prevention of type 2 diabetes mellitus. Recent findings Several major studies investigating angiotensn II receptor blocker or angiotensin-converting enzyme inhibitor use in either hypertensive or heart failure patients have found lower incidence of type 2 diabetes mellitus when compared with placebo, beta-blocker, calcium-channel blocker or diuretic. None of these trials, however, studied prevention of diabetes as a primary endpoint. The Dream Trial and upcoming NAVIGATOR, ONTARGET/TRANSCEND trials specifically look at the prevention of diabetes as a primary endpoint. Several studies have evaluated possible mechanisms of how the renin-angiotensin-aldosterone system can alter insulin sensitivity and glycemic control. Summary This review will focus on the recent literature that demonstrates renin-angiotensin-aldosterone system modulation and its effects on diabetes prevention, glycemic control and insulin sensitivity, as well as possible mechanisms for achieving this goal.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据